Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDK | P21741 | 4/20 | 0.45 |
| ▸ | BDNF | P23560 | 3/20 | 0.45 |
| ▸ | PTN | P21246 | 2/20 | 0.45 |
| ▸ | LGALS3 | P17931 | 5/20 | 0.44 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.44 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | CD69 | Q07108 | 1/20 | 0.41 |
| ▸ | FGF1 | P05230 | 1/20 | 0.41 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.40 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.38 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20291137 | 0.98 | LGALS3 (0.45) | MDKBDNFPTNLGALS3LGALS8 | |
| SCHEMBL16269841 | 0.89 | LGALS3 (0.42) | MDKBDNFPTNLGALS3LGALS8 | |
| SCHEMBL21316642 | 0.89 | LGALS3 (0.42) | MDKBDNFPTNLGALS3LGALS8 | |
| SCHEMBL22472735 | 0.89 | LGALS3 (0.42) | MDKBDNFPTNLGALS3LGALS8 | |
| SCHEMBL20122304 | 0.89 | LGALS3 (0.42) | MDKBDNFPTNLGALS3LGALS8 | |
| SCHEMBL19928682 | 0.89 | LGALS3 (0.42) | MDKBDNFPTNLGALS3LGALS8 | |
| SCHEMBL19852803 | 0.87 | LGALS3 (0.45) | MDKBDNFPTNLGALS3LGALS8 | |
| SCHEMBL21480237 | 0.87 | LGALS3 (0.44) | MDKBDNFPTNLGALS3LGALS8 | |
| SCHEMBL21316636 | 0.86 | ALDH1A1 (0.42) | MDKBDNFPTNLGALS3LGALS8 | |
| SCHEMBL18737419 | 0.86 | MDK (0.41) | MDKBDNFPTNLGALS3LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673974-B2 | Glycophospholipid polymeric network and use thereof | BAUSCH & LOMB INCORPORATED (US) | 2023-06-13 | — | — | US | disclosed |
| US-20200339710-A1 | GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF | BAUSCH HEALTH US, LLC | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673974-B2 | Glycophospholipid polymeric network and use thereof | ALG1, CSGALNACT1, FUT5 | MDK 3567/4885BDNF 4645/4885PTN 219/4885 |
| US-20200339710-A1 | GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF | ALG1, CSGALNACT1, FUT5 | MDK 3567/4885BDNF 4645/4885PTN 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.